Solutions for successful patient recruitment in early stage clinical trials
-
1
Arensia Exploratory Medicine, Clinical operations, Georgia
-
2
Arensia Exploratory Medicine, Clinical operations, Germany
Background: In the today’s fast-changing world of drug development, fast patient recruitment is a compelling challenge in
early stage clinical trials. The need for fast go/no-go decisions has triggered the early involvement of patients in exploratory
trials where no treatment benefit is granted but a complex trial design is favoured. Consequently, patient recruitment became a
speed limiting factor of drug development programs.
Methods: The reporting clinical research organization has built a network of Phase I research units in Eastern Europe. Analysis
of recruitment in selected trials in inflammatory, oncology and infectious diseases trials are presented, analysing obstacles and
offering efficient solutions.
Results: 1748 patients were enrolled 2011-2016 in 113 exploratory trials. Multi-fold patient rates compared to other sites were
achieved.
INSERT IMAGE 1
*ARENSIA, single site, specializing in early clinical development
**average number of patients of active sites
Discussion: High single centre patient recruitment rates were achieved using specific approaches in early stage clinical trials:
geographic location, knowledge of the local health care systems and high motivation of the investigating teams. The creation of
a tailor-made recruitment strategy alongside with post-trial treatment, recommendations for suitable trial designs, familiarity
with the patient population and patient compensation are key factors for the speed of patient recruitment and retention.
Keywords:
early stage,
recruitment,
solution
Conference:
EUFEMED 2017, London, United Kingdom, 17 May - 19 May, 2017.
Presentation Type:
Poster
Topic:
EUFEMED 2017 CONFERENCE
Citation:
Kakabadze
T and
Bischoff
A
(2019). Solutions for successful patient recruitment in early stage clinical trials.
Front. Pharmacol.
Conference Abstract:
EUFEMED 2017.
doi: 10.3389/conf.fphar.2017.62.00013
Copyright:
The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers.
They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.
The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.
Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.
For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.
Received:
29 Aug 2017;
Published Online:
25 Jan 2019.
*
Correspondence:
Dr. Angela Bischoff, Arensia Exploratory Medicine, Clinical operations, Dusseldorf, Germany, angela.bischoff@arensia-em.com